Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen
Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on Avance Nerve Graft, a pivotal regulatory inflection point. The BLA submission features over a decade of real-world outcomes, robust manufacturing validation, and clinical recovery rates in the low-80% range.
AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 76.4% in AxoGen (AXGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined
Axogen is compounding business capital at increasing returns which was reflected in Q2 earnings. The stock remains in a down-trend with investors compressing multiples paid on capital invested into the business. The range of potential outcomes remains broad which coincides with historical trends seen in market for this name.
Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript
Axogen, Inc. (NASDAQ:AXGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Jens Schroeder Kemp - Chief Marketing Officer Lindsey Hartley - Chief Financial Officer Michael D. Dale - President, CEO & Director Rick Ditto - Corporate Participant Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Christopher Thomas Pasquale - Nephron Research LLC David Louis Turkaly - Citizens JMP Securities, LLC, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Michael Anthony Sarcone - Jefferies LLC, Research Division Ross Everett Osborn - Cantor Fitzgerald & Co., Research Division Operator [Audio Gap] Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Lindsey Hartley, Chief Financial Officer.
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.05 per share a year ago.
AxoGen (AXGN) Earnings Expected to Grow: Should You Buy?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
AxoGen (AXGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.06 per share a year ago.
Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript
Axogen, Inc. (NASDAQ:AXGN ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Jens Kemp - Chief Marketing Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens Kemp, Chief Marketing Officer.
AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out?
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
